Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioNTech SEBNTX · Entity 3181 | Director | June 26, 2026 | June 26, 2026 |
| INCYTE CORPINCY · Entity 3182 | Director | June 10, 2025 | June 12, 2025 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | Director | July 29, 2022 | August 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioNTech SE
Report date June 26, 2026 · Filed June 26, 2026
This filing explicitly reported no securities owned.
INCYTE CORP
Report date June 10, 2025 · Filed June 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,871 |
Reported balance
After 2025-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-10 · Tax withholding · Disposed 849 · Balance 4,871 F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. |
| Common StockSEC Table I · non-derivative | Direct | 7,389 |
Reported balance
After 2025-06-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-06-10 · Grant · Acquired 2,518 · Balance 7,389 F2: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F3: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
| Non Qualfied Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.07 · Expires 2035-06-09 | Direct | 9,216 |
Reported balance
After 2025-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-10 · Grant · Acquired 9,216 · Balance 9,216 F4: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.
F2: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.
F3: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F4: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).
Rubius Therapeutics, Inc.
Report date July 29, 2022 · Filed August 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2032-07-28 | Direct | 50,000 |
Reported balance
After 2022-07-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-29 · Grant · Acquired 50,000 · Balance 50,000 F1: This option shall vest in equal quarterly installments over the twelve quarters following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in equal quarterly installments over the twelve quarters following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2025 Filed Jun 12, 2025 20:28 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon Qualfied Stock Option (right to buy) · Derivative | 9,216 | $0.00 Strike: $70.07 | $0.00 |
DisclosureSEC source: 0001628280-25-031001 · wk-form4_1749760105.xml · derivative · entry 3 Schaffert Susanne · CIK 0001938363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,216 Underlying: Common Stock · 9,216 shares Expires 2035-06-09 F4 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:28 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-031001 · wk-form4_1749760105.xml · nonDerivative · entry 2 Schaffert Susanne · CIK 0001938363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,389 F2 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F3 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:28 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 849 | $70.07 | $59,489.43 |
DisclosureSEC source: 0001628280-25-031001 · wk-form4_1749760105.xml · nonDerivative · entry 1 Schaffert Susanne · CIK 0001938363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,871 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:15 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon Qualfied Stock Option (right to buy) · Derivative | 12,517 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0000879169-24-000093 · wk-form4_1718381692.xml · derivative · entry 3 Schaffert Susanne · CIK 0001938363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,517 Underlying: Common Stock · 12,517 shares Expires 2034-06-11 F4 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:15 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,830 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-24-000093 · wk-form4_1718381692.xml · nonDerivative · entry 2 Schaffert Susanne · CIK 0001938363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,720 F2 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F3 · balance_after: Including this grant, this includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:15 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 752 | $59.94 | $45,074.88 |
DisclosureSEC source: 0000879169-24-000093 · wk-form4_1718381692.xml · nonDerivative · entry 1 Schaffert Susanne · CIK 0001938363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,890 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,294 | $0.00 Strike: $61.44 | $0.00 |
DisclosureSEC source: 0001209191-23-037796 · doc4.xml · derivative · entry 3 Schaffert Susanne · CIK 0001938363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,294 Underlying: Common Stock · 11,294 shares Expires 2033-06-13 F4 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 488 | $61.44 | $29,982.72 |
DisclosureSEC source: 0001209191-23-037796 · doc4.xml · nonDerivative · entry 2 Schaffert Susanne · CIK 0001938363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,642 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table 1 as common stock F3 · balance_after: This includes the 2,505 restricted stock units issubale as common stock, that have not yet vested, being reported on this filing. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037796 · doc4.xml · nonDerivative · entry 1 Schaffert Susanne · CIK 0001938363 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,130 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,751 | $0.00 Strike: $68.83 | $0.00 |
DisclosureSEC source: 0001209191-22-052801 · doc4.xml · derivative · entry 2 Schaffert Susanne · CIK 0001938363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,751 Underlying: Common Stock · 6,751 shares Expires 2032-10-02 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-052801 · doc4.xml · nonDerivative · entry 1 Schaffert Susanne · CIK 0001938363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,625 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| July 29, 2022 Filed Aug 1, 2022 17:38 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001709401-22-000004 · wf-form4_165938990864068.xml · derivative · entry 1 Schaffert Susanne · CIK 0001938363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-07-28 F1 · derivative.exercise_date: This option shall vest in equal quarterly installments over the twelve quarters following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.